U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H26N6O4S
Molecular Weight 506.577
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAPRIZOSIN

SMILES

COC1=CC2=C(C(N)=NC(=N2)N3CCC4=C(C3)C=CC=C4NS(C)(=O)=O)C(C5=CC=CC=N5)=C1OC

InChI

InChIKey=OLYXPBZBZBVRGD-UHFFFAOYSA-N
InChI=1S/C25H26N6O4S/c1-34-20-13-19-22(21(23(20)35-2)18-8-4-5-11-27-18)24(26)29-25(28-19)31-12-10-16-15(14-31)7-6-9-17(16)30-36(3,32)33/h4-9,11,13,30H,10,12,14H2,1-3H3,(H2,26,28,29)

HIDE SMILES / InChI

Molecular Formula C25H26N6O4S
Molecular Weight 506.577
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Taprizosin (also known as UK-338,003) is an alpha1A-adrenoceptor antagonist that was developed for the treatment of benign prostatic hyperplasia. However, this compound possesses poor oral absorption.

Approval Year

PubMed

PubMed

TitleDatePubMed
Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
2007 Aug
Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): the rational use of ex vivo intestine to predict in vivo absorption.
2008 Jan
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:42:22 GMT 2023
Edited
by admin
on Sat Dec 16 16:42:22 GMT 2023
Record UNII
EQ8YV2D86Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TAPRIZOSIN
INN  
INN  
Official Name English
taprizosin [INN]
Common Name English
UK-338,003
Code English
UK-338003
Code English
Classification Tree Code System Code
NCI_THESAURUS C29713
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
NCI_THESAURUS C29707
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
Code System Code Type Description
FDA UNII
EQ8YV2D86Y
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
PRIMARY
EPA CompTox
DTXSID70175274
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
PRIMARY
CAS
210538-44-6
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL401796
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
PRIMARY
PUBCHEM
6433102
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
PRIMARY
INN
8286
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
PRIMARY
NCI_THESAURUS
C66580
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
PRIMARY
SMS_ID
300000034377
Created by admin on Sat Dec 16 16:42:22 GMT 2023 , Edited by admin on Sat Dec 16 16:42:22 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
WEAK
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

Tmax PHARMACOKINETIC ORAL ADMINISTRATION